Compare CSTL & ORC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | ORC |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2019 | 2013 |
| Metric | CSTL | ORC |
|---|---|---|
| Price | $40.31 | $8.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $46.00 | $7.50 |
| AVG Volume (30 Days) | 331.6K | ★ 6.7M |
| Earning Date | 02-26-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 17.29% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | ★ $343,530,000.00 | $80,187,000.00 |
| Revenue This Year | $2.54 | $90.64 |
| Revenue Next Year | N/A | $78.88 |
| P/E Ratio | ★ N/A | $14.52 |
| Revenue Growth | ★ 10.15 | 5.93 |
| 52 Week Low | $14.59 | $5.69 |
| 52 Week High | $42.18 | $9.01 |
| Indicator | CSTL | ORC |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 83.03 |
| Support Level | $38.73 | $7.73 |
| Resistance Level | $41.60 | $7.59 |
| Average True Range (ATR) | 1.58 | 0.17 |
| MACD | -0.12 | 0.09 |
| Stochastic Oscillator | 62.75 | 97.06 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.